Scholars Central

Research articlePublished 2019

Final Efficacy Results of a Randomized Phase II Study of Recombinant Interleukin-21 Compared to Decarbonize in Patients with Recurrent or Metastatic Melanoma

Authors: Dr.Teresa M. Petrella

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Interleukin-21(IL-21) is a T-cell derived cytokine with antitumour activitydependent on NK cells or CD8+ T cells. A previous phase II study demonstratedan overall response rate (ORR) of 22.5% in previously untreated patients withmetastatic melanoma. We conducted a multi-centre randomized phase II study inmetastatic melanoma patients to evaluate the efficacy, toxicity, immunogenicityand biomarkers associated with response to IL-21 versus dacarbazine (DTIC).

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in International Journal of Inflammation, Cancer and Integrative Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Inflammation, Cancer and Integrative Therapy
  • SubjectImmunology & Microbiology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Dr.Teresa M. Petrella”